1. |
Lee JH, Kim YA, Lee Y, et al. Association between interarm blood pressure differences and diabetic retinopathy in patients with type 2 diabetes[J/OL]. Diab Vasc Dis Res, 2020, 17(7): 1479164120945910[2020-07-01]. https://pubmed.ncbi.nlm.nih.gov/32746630/. DOI: 10.1177/1479164120945910.
|
2. |
Sardarinia M, Asgari S, Hizomi Arani R, et al. Incidence and risk factors of severe non-proliferative/proliferative diabetic retinopathy: more than a decade follow up in the tehran lipids and glucose study[J]. J Diabetes Investig, 2022, 13(2): 317-327. DOI: 10.1111/jdi.13647.
|
3. |
Roy MS, Affouf M. Six-year progression of retinopathy and associated risk factors in African American patients with type 1 diabetes mellitus: the New Jersey 725[J]. Arch Ophthalmol, 2006, 124(9): 1297-1306. DOI: 10.1001/archopht.124.9.1297.
|
4. |
Lee CC, Hsing SC, Lin YT, et al. The importance of close follow-up in patients with early-grade diabetic retinopathy: a Taiwan population-based study grading via deep learning model[J/OL]. Int J Environ Res Public Health, 2021, 18(18): 9768[2021-09-16]. https://pubmed.ncbi.nlm.nih.gov/34574686/. DOI: 10.3390/ijerph18189768.
|
5. |
Perais J, Agarwal R, Evans JR, et al. Prognostic factors for the development and progression of proliferative diabetic retinopathy in people with diabetic retinopathy[J/OL]. Cochrane Database Syst Rev, 2023, 2(2): CD013775[2023-02-22]. https://pubmed.ncbi.nlm.nih.gov/36815723/. DOI: 10.1002/14651858.CD013775.pub2.
|
6. |
Boef AG, Dekkers OM, le Cessie S. Mendelian randomization studies: a review of the approaches used and the quality of reporting[J]. Int J Epidemiol, 2015, 44(2): 496-511. DOI: 10.1093/ije/dyv071.
|
7. |
Lee K, Lim CY. Mendelian randomization analysis in observational epidemiology[J]. J Lipid Atheroscler, 2019, 8(2): 67-77. DOI: 10.12997/jla.2019.8.2.67.
|
8. |
Su Z, Wu Z, Liang X, et al. Diabetic retinopathy risk in patients with unhealthy lifestyle: a mendelian randomization study[J/OL]. Front Endocrinol (Lausanne), 2023, 13: 1087965[2023-01-17]. https://pubmed.ncbi.nlm.nih.gov/36733810/. DOI: 10.3389/fendo.2022.1087965.
|
9. |
Cai J, He L, Wang H, et al. Genetic liability for prescription opioid use and risk of cardiovascular diseases: a multivariable mendelian randomization study[J]. Addiction, 2022, 117(5): 1382-1391. DOI: 10.1111/add.15767.
|
10. |
Hemani G, Zheng J, Elsworth B, et al. The MR-Base platform supports systematic causal inference across the human phenome[J/OL]. Elife, 2018, 7: e34408[2018-05-30]. https://pubmed.ncbi.nlm.nih.gov/29846171/. DOI: 10.7554/eLife.34408.
|
11. |
Burgess S, Thompson SG. Interpreting findings from mendelian randomization using the MR-Egger method[J]. Eur J Epidemiol, 2017, 32(5): 377-389. DOI: 10.1007/s10654-017-0255-x.
|
12. |
Bowden J, Del Greco MF, Minelli C, et al. Assessing the suitability of summary data for two-sample mendelian randomization analyses using MR-Egger regression: the role of the I2 statistic[J]. Int J Epidemiol, 2016, 45(6): 1961-1974. DOI: 10.1093/ije/dyw220.
|
13. |
Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression[J]. Int J Epidemiol, 2015, 44(2): 512-525. DOI: 10.1093/ije/dyv080.
|
14. |
Pierce BL, Burgess S. Efficient design for mendelian randomization studies: subsample and 2-sample instrumental variable estimators[J]. Am J Epidemiol, 2013, 178(7): 1177-1184. DOI: 10.1093/aje/kwt084.
|
15. |
Bowden J, Davey Smith G, Haycock PC, et al. Consistent estimation in mendelian randomization with some invalid instruments using a weighted median estimator[J]. Genet Epidemiol, 2016, 40(4): 304-314. DOI: 10.1002/gepi.21965.
|
16. |
Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy[J]. Diabetes Care, 2012, 35(3): 556-564. DOI: 10.2337/dc11-1909.
|
17. |
Ting DS, Cheung GC, Wong TY. Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review[J]. Clin Exp Ophthalmol, 2016, 44(4): 260-277. DOI: 10.1111/ceo.12696.
|
18. |
Amarnath S, Starr A, Chukkalore D, et al. The association between gastroesophageal reflux disease and non-small cell lung cancer: a retrospective case-control study[J]. Gastroenterology Res, 2022, 15(4): 173-179. DOI: 10.14740/gr1537.
|
19. |
Bhargava M, Ikram MK, Wong TY. How does hypertension affect your eyes?[J]. J Hum Hypertens, 2012, 26(2): 71-83. DOI: 10.1038/jhh.2011.37.
|
20. |
Pournaras CJ, Rungger-Brändle E, Riva CE, et al. Regulation of retinal blood flow in health and disease[J]. Prog Retin Eye Res, 2008, 27(3): 284-330. DOI: 10.1016/j.preteyeres.2008.02.002.
|
21. |
Sun C, Wang JJ, Mackey DA, et al. Retinal vascular caliber: systemic, environmental, and genetic associations[J]. Surv Ophthalmol, 2009, 54(1): 74-95. DOI: 10.1016/j.survophthal.2008.10.003.
|
22. |
Kawasaki R, Cheung N, Wang JJ, et al. Retinal vessel diameters and risk of hypertension: the multiethnic study of atherosclerosis[J]. J Hypertens, 2009, 27(12): 2386-2393. DOI: 10.1097/HJH.0b013e3283310f7e.
|
23. |
Katsi V, Marketou M, Vlachopoulos C, et al. Impact of arterial hypertension on the eye[J]. Curr Hypertens Rep, 2012, 14(6): 581-590. DOI: 10.1007/s11906-012-0283-6.
|
24. |
Zhang HN, Xu QQ, Thakur A, et al. Endothelial dysfunction in diabetes and hypertension: role of microRNAs and long non-coding RNAs[J]. Life Sci, 2018, 213: 258-268. DOI: 10.1016/j.lfs.2018.10.028.
|
25. |
Tan TE, Wong TY. Diabetic retinopathy: Looking forward to 2030[J/OL]. Front Endocrinol (Lausanne), 2023, 13: 1077669[2023-01-09]. https://pubmed.ncbi.nlm.nih.gov/36699020/. DOI: 10.3389/fendo.2022.1077669.
|